🚀 VC round data is live in beta, check it out!
MapLight Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for MapLight Therapeutics and similar public comparables like BridgeBio Oncology, Polaris Group, Agomab Therapeutics, Nika Pharmaceuticals and more.
MapLight Therapeutics Overview
About MapLight Therapeutics
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.
Founded
2018
HQ
Employees
109
Website
Sectors
Financials (LTM)
EV
$576M
MapLight Therapeutics Financials
MapLight Therapeutics reported last 12-month revenue of — and negative EBITDA of ($180M).
In the same LTM period, MapLight Therapeutics generated — in gross profit, ($180M) in EBITDA losses, and had net loss of ($167M).
MapLight Therapeutics P&L
In the most recent fiscal year, MapLight Therapeutics reported revenue of — and EBITDA of ($169M).
MapLight Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($180M) | XXX | ($169M) | XXX | XXX | XXX |
| Net Profit | ($167M) | XXX | ($161M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
MapLight Therapeutics Stock Performance
MapLight Therapeutics has current market cap of $797M, and enterprise value of $576M.
MapLight Therapeutics' stock price is $17.57.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $576M | $797M | 0.0% | XXX | XXX | XXX | $-3.55 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMapLight Therapeutics Valuation Multiples
MapLight Therapeutics trades at (3.2x) EV/EBITDA.
MapLight Therapeutics Financial Valuation Multiples
As of March 29, 2026, MapLight Therapeutics has market cap of $797M and EV of $576M.
Equity research analysts estimate MapLight Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MapLight Therapeutics has a P/E ratio of (4.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $797M | XXX | $797M | XXX | XXX | XXX |
| EV (current) | $576M | XXX | $576M | XXX | XXX | XXX |
| EV/EBITDA | (3.2x) | XXX | (3.4x) | XXX | XXX | XXX |
| EV/EBIT | (3.3x) | XXX | (3.4x) | XXX | XXX | XXX |
| P/E | (4.8x) | XXX | (4.9x) | XXX | XXX | XXX |
| EV/FCF | (3.7x) | XXX | (4.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified MapLight Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
MapLight Therapeutics Margins & Growth Rates
MapLight Therapeutics' revenue in the last fiscal year grew by —.
MapLight Therapeutics' revenue per employee in the last FY averaged $0.0M.
MapLight Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 18% | XXX | 24% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
MapLight Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BridgeBio Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Polaris Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Agomab Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Nika Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| KalVista Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MapLight Therapeutics M&A Activity
MapLight Therapeutics acquired XXX companies to date.
Last acquisition by MapLight Therapeutics was on XXXXXXXX, XXXXX. MapLight Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by MapLight Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMapLight Therapeutics Investment Activity
MapLight Therapeutics invested in XXX companies to date.
MapLight Therapeutics made its latest investment on XXXXXXXX, XXXXX. MapLight Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by MapLight Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout MapLight Therapeutics
| When was MapLight Therapeutics founded? | MapLight Therapeutics was founded in 2018. |
| Where is MapLight Therapeutics headquartered? | MapLight Therapeutics is headquartered in United States. |
| How many employees does MapLight Therapeutics have? | As of today, MapLight Therapeutics has over 109 employees. |
| Is MapLight Therapeutics publicly listed? | Yes, MapLight Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of MapLight Therapeutics? | MapLight Therapeutics trades under MPLT ticker. |
| When did MapLight Therapeutics go public? | MapLight Therapeutics went public in 2025. |
| Who are competitors of MapLight Therapeutics? | MapLight Therapeutics main competitors are BridgeBio Oncology, Polaris Group, Agomab Therapeutics, Nika Pharmaceuticals. |
| What is the current market cap of MapLight Therapeutics? | MapLight Therapeutics' current market cap is $797M. |
| Is MapLight Therapeutics profitable? | No, MapLight Therapeutics is not profitable. |
| What is the current EBITDA of MapLight Therapeutics? | MapLight Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of MapLight Therapeutics? | Current EBITDA multiple of MapLight Therapeutics is (3.2x). |
| What is the current FCF of MapLight Therapeutics? | MapLight Therapeutics' last 12 months FCF is ($155M). |
| What is the current EV/FCF multiple of MapLight Therapeutics? | Current FCF multiple of MapLight Therapeutics is (3.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.